Full Press Release Details
LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:
| Piper Sandler 37 th Annual Healthcare Conference | |
| Format: | Fireside Chat & 1x1 Meetings |
| Date: | Tuesday, December 2, 2025 |
| Time: | 11:30 AM EST |
| Evercore ISI 8 th Annual Healthcare Conference | |
| Format: | Fireside Chat & 1x1 Meetings |
| Date: | Wednesday, December 3, 2025 |
| Time: | 3:50 PM EST |
Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.
Investors are invited to review the company corporate deck found on the Events & Presentations page, as well as the replay from the recent virtual KOL Event to discuss EQ504: A Novel Aryl Hydrocarbon Receptor (AhR) Modulator for Ulcerative Colitis.
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.
For more information, visit www.equilliumbio.com.
LifeSci Advisors, LLC